FDA approves first non-addictive pain medication
The FDA has approved Vertex Pharmaceuticals' Journavx, the first new medication to be approved in more than two decades, to treat adults with acute pain. The medication is the first of its kind, with non-addictive properties and provides an alternative to opioids.
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Wall Street also was waiting to see whether President Donald Trump would follow through on his pledge to enact tariffs on ...
Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
H.C. Wainwright raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $550 from $535 and keeps a Buy rating on the shares after ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback